

is to determine eligibility for the 340B program. This information is received and verified according to 340B requirements and entered into the 340B database. Accurate records are critical to implementation of the 340B legislation especially to prevent diversion and duplicate discounts. To maintain accurate records, the OPA requests

entities to submit modifications to any administrative information that they submitted when initially enrolling into the program. The burden requirement for these processes is minimal.

Contract Pharmacy Self-Certification

In order to ensure that drug manufacturers and drug wholesalers recognize contract pharmacy

arrangements, covered entities that elect to utilize a contract pharmacy are required to submit to OPA a self-certification form similar to the registration form that they have signed an agreement with the contract pharmacy.

The Estimates of annualized burden are as follows:

Reporting requirement	Number of respondents	Responses per respondent	Total responses	Hours per response	Total burden hours
DSH & Children’s Hospital Enrollment, Additions & Recertifications					
340B Program Registrations & Certifications for Disproportionate Share Hospitals	70	1	70	.25	17.5
340B Program Registrations & Certifications for Children’s Hospitals	80	1	80	.25	20
Certifications to Enroll DSH & Children’s Hospitals Out-patient facilities to 340B Program	180	1	180	.083	14.94
DSH & Children’s Hospitals’ Annual Recertification	937	1	937	.5	468.5
Registration for Entities Other Than Hospitals & Recertifications					
340B Registration Form (Family Planning, STD, TB, and others)	170	1	170	.083	14.11
Family Planning Annual Recertification	85	47	3995	.083	331.59
STD & TB Annual Recertification	111	11	1221	.083	101.34
Other Entity Annual Recertification for entities other than DSHs, FP, STD or TB entities	400	10	4000	.083	332
Submission of Administrative Changes for any entity	460	1	460	.083	38.18
Contracted Pharmacy Services Registration & Recertifications					
Contracted Pharmacy Services Registration	2000	1	2000	.083	166
Total	* 4493	13,313	1504.16

* The total number of respondents may be overestimated since we are unable to avoid duplication of respondents who submit information to the OPA over the course of participation in the 340B Drug Pricing Program, via the initial registration process to any updates/modifications and enrolling contract pharmacies, if applicable, to the recertification process.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to the desk officer for HRSA, either by e-mail to OIRA_submission@omb.eop.gov or by fax to 202-395-6974. Please direct all correspondence to the “attention of the desk officer for HRSA.”

Dated: August 5, 2009.

Alexandra Huttinger,
Director, Division of Policy Review and Coordination.

[FR Doc. E9-19381 Filed 8-12-09; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Health Promotion and Disease Prevention Research Centers, Special Interest Project Competitive Supplements (SIPS) (U48 Panels N, O and P), RFA-DP09-101SUPP09, Initial Review

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

Time and Dates:

- 9 a.m.–5 p.m., August 5, 2009 (closed).
- 9 a.m.–5 p.m., August 6, 2009 (closed).
- 9 a.m.–5 p.m., August 7, 2009 (closed).

Place: Westin Hotel, 3377 Peachtree Road, NE., Atlanta, GA, 30326, Telephone (678) 500-3100.

Status: The meeting will be closed to the public in accordance with provisions set

forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of the application received in response to “Health Promotion and Disease Prevention Research Centers, Special Interest Project Competitive Supplements (SIPS) (U48 Panels N, O and P), RFA-DP09-101SUPP09, initial review.”

Contact Person for More Information: Brenda Colley-Gilbert, Ph.D., Director, Extramural Research Program Office, CCH, 47770 Buford Highway, MS K-92, Atlanta, GA 30341, Telephone (770) 488-8390.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9-19293 Filed 8-12-09; 8:45 am]

BILLING CODE 4163-18-P